Ipilimumab et cancer bronchique métastatique: peut-on changer l'histoire naturelle de la maladie ?

A. Boyer; L. Greillier; H. Barazzutti; P. Tomasini; F. Barlesi

doi:10.1016/j.rmr.2014.12.006

Ipilimumab et cancer bronchique métastatique: peut-on changer l'histoire naturelle de la maladie ?

A. Boyer, L. Greillier, H. Barazzutti, P. Tomasini, F. Barlesi

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. Thistreatment is being evaluated in non-small cell lung cancer.Case report.-We report a case of a stage IV adenocarcinoma patient randomized in 2008 in thephase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with car-boplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieveda complete response with ipilimumab as maintenance therapy. However, it was complicatedby grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this completeresponse persists after 6 years.Conclusions.-Our case illustrates the contribution of immunotherapy at least in some patients.The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacyremain to be defined.

Titre traduit de la contribution	Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease?
langue originale	Français
Pages (de - à)	949-952
Nombre de pages	4
journal	Revue des Maladies Respiratoires
Volume	32
Numéro de publication	9
Les DOIs	https://doi.org/10.1016/j.rmr.2014.12.006
état	Publié - 1 nov. 2015
Modification externe	Oui

mots-clés

Bronchial adenocarcinoma
Immunotherapy
Ipilimumab
Remission induction

Accès au document

10.1016/j.rmr.2014.12.006

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{1e6667ea844d46a0a1f72c4c82500b7b,

title = "Ipilimumab et cancer bronchique m{\'e}tastatique: peut-on changer l'histoire naturelle de la maladie ?",

abstract = "Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. Thistreatment is being evaluated in non-small cell lung cancer.Case report.-We report a case of a stage IV adenocarcinoma patient randomized in 2008 in thephase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with car-boplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieveda complete response with ipilimumab as maintenance therapy. However, it was complicatedby grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this completeresponse persists after 6 years.Conclusions.-Our case illustrates the contribution of immunotherapy at least in some patients.The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacyremain to be defined.",

keywords = "Bronchial adenocarcinoma, Immunotherapy, Ipilimumab, Remission induction",

author = "A. Boyer and L. Greillier and H. Barazzutti and P. Tomasini and F. Barlesi",

note = "Publisher Copyright: {\textcopyright} 2015 SPLF.",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.rmr.2014.12.006",

language = "Fran{\c c}ais",

volume = "32",

pages = "949--952",

journal = "Revue des Maladies Respiratoires",

issn = "0761-8425",

number = "9",

}

TY - JOUR

T1 - Ipilimumab et cancer bronchique métastatique

T2 - peut-on changer l'histoire naturelle de la maladie ?

AU - Boyer, A.

AU - Greillier, L.

AU - Barazzutti, H.

AU - Tomasini, P.

AU - Barlesi, F.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. Thistreatment is being evaluated in non-small cell lung cancer.Case report.-We report a case of a stage IV adenocarcinoma patient randomized in 2008 in thephase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with car-boplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieveda complete response with ipilimumab as maintenance therapy. However, it was complicatedby grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this completeresponse persists after 6 years.Conclusions.-Our case illustrates the contribution of immunotherapy at least in some patients.The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacyremain to be defined.

AB - Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. Thistreatment is being evaluated in non-small cell lung cancer.Case report.-We report a case of a stage IV adenocarcinoma patient randomized in 2008 in thephase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with car-boplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieveda complete response with ipilimumab as maintenance therapy. However, it was complicatedby grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this completeresponse persists after 6 years.Conclusions.-Our case illustrates the contribution of immunotherapy at least in some patients.The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacyremain to be defined.

KW - Bronchial adenocarcinoma

KW - Immunotherapy

KW - Ipilimumab

KW - Remission induction

UR - http://www.scopus.com/inward/record.url?scp=84947742288&partnerID=8YFLogxK

U2 - 10.1016/j.rmr.2014.12.006

DO - 10.1016/j.rmr.2014.12.006

M3 - Article

C2 - 25725978

AN - SCOPUS:84947742288

SN - 0761-8425

VL - 32

SP - 949

EP - 952

JO - Revue des Maladies Respiratoires

JF - Revue des Maladies Respiratoires

IS - 9

ER -